Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent
Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial
ETP-ALL May Be Linked To Acute Myeloid Leukemia
CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup
BRCA1 and BRCA2 Mutations Linked To Higher Survival
Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease
Chromosomal Abnormalities Predict Long Median Survival
Analysis Shows No Mortality Benefit From Regular PSA Screening
Ovarian Cancer Symptom Indices May Need to be Re-Evaluated
Self-Collected Pap Smear Tests Could Advance HPV Screening
Trials Approved by NCI CTEP For the Month of January
Palmetto Establishes Coverage For Thyroid Genomic Test
FDA Approves Inlyta Pill For Renal Cell Carcinoma
Trending Stories
- Trump 2016: A look back at the 45th president’s impact on oncology
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - When cigarette filters were made of asbestos
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting
- Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
